GlassScriptPhysician profile
Leslie A Spry
NPI 1679522528
$3,186.24
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.50 · 2020: $13.14 · 2021: $324 · 2022: $373 · 2023: $55.85 · 2024: $2,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,024 · Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,023.72 |
| Food and Beverage | $352.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $2,189.72 | 2024 | |
| Aurinia Pharma U.S., INC. | $133.22 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.38 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $81.13 | 2020-2022 | |
| Amgen INC. | $76.98 | 2019-2024 | Tavneos |
| Boston Scientific Corporation | $64.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.38 | 2021-2022 | |
| Baxter Healthcare | $43.98 | 2024 | |
| Fresenius USA Marketing, INC. | $43.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.25 | 2021 | |
| Seagen INC. | $34.07 | 2019-2023 | Adcetris |
| Travere Therapeutics, INC. | $32.95 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $28.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $27.25 | 2022 | |
| Rockwell Medical, INC. | $27.22 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.20 | 2022 | |
| Exelixis INC. | $20.63 | 2019 | |
| Bard Peripheral Vascular, INC. | $19.59 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.77 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.67 | 2021 | |
| Eisai INC. | $15.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.85 | 2021 | |
| Novo Nordisk INC | $15.62 | 2024 | Ozempic |
| Janssen Biotech, INC. | $15.23 | 2022 | |
| Allergan, INC. | $15.21 | 2019 | |
| Esperion Therapeutics, INC. | $14.74 | 2021 | |
| Nxstage Medical, INC. | $12.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.45 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Spry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.